GlassScriptPhysician profile
Mark N Wong
NPI 1821054081
$70,833.28
in general payments reported to CMS, 2019-2025
29 companies · $6,066 in 2025
The $6,066 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $14K · 2022: $12K · 2023: $2,212 · 2024: $13K · 2025: $6,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,900 · Food and Beverage: $6,784 · Consulting Fee: $3,420 · Travel and Lodging: $1,957 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,900.00 |
| Food and Beverage | $6,783.90 |
| Consulting Fee | $3,420.00 |
| Travel and Lodging | $1,956.69 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $57,571.91 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Mallinckrodt Hospital Products INC. | $3,914.85 | 2020-2025 | Terlivaz |
| Sirtex Medical INC | $3,769.79 | 2021-2023 | Sir-Spheres Microspheres |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,142.25 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $1,228.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $456.79 | 2019-2023 | Linzess, Creon |
| Ipsen Biopharmaceuticals, INC | $275.26 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $170.53 | 2020-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $142.49 | 2023 | Livtencity, Entyvio |
| Intra-Sana Laboratories | $141.10 | 2022-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Shionogi INC | $127.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.24 | 2019-2020 | |
| Dova Pharmaceuticals | $112.92 | 2019 | |
| Genzyme Corporation | $110.51 | 2019 | |
| Mallinckrodt Enterprises LLC | $108.70 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.38 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $51.01 | 2023 | Dupixent |
| Janssen Biotech, INC. | $49.14 | 2023 | Stelara |
| Fujifilm Healthcare Americas Corporation | $45.89 | 2024 | Utaswako Afp-L3 |
| Trisalus Life Sciences, INC. | $41.28 | 2023 | Trinav Infusion System |
| Celgene Corporation | $29.31 | 2022-2023 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $24.64 | 2022 | |
| Eisai INC. | $23.93 | 2019 | |
| Ardelyx, INC. | $22.12 | 2023 | Ibsrela |
| Vibrant Gastro, INC. | $20.05 | 2024 | Vibrant Starter Kit |
| Exact Sciences Corporation | $16.78 | 2023 | Cologuard Collection Kit |
| Bard Peripheral Vascular, INC. | $16.25 | 2024 | Denali Vena Cava Filter |
| Emd Serono, INC. | $14.29 | 2021 | |
| Travere Therapeutics, INC. | $7.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.